5α-Reductase Inhibitors

5α-reductase inhibitors (5-ARIs), including finasteride and dutasteride, are approved by the U.S. Food and Drug Administration for treating benign prostatic hyperplasia and androgenic alopecia. These medications inhibit the enzyme 5α-reductase, reducing the conversion of testosterone into dihydrotestosterone, a hormone implicated in prostate enlargement and hair loss. This educational activity discusses the indications, mechanism of action, potential adverse events, and contraindications associated with 5-ARIs. The activity also covers off-label uses, appropriate dosing recommendations, and monitoring strategies to mitigate drug interactions and ensure patient safety.